J
Julie S. Moyers
Researcher at Eli Lilly and Company
Publications - 24
Citations - 3336
Julie S. Moyers is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 9, co-authored 18 publications receiving 2739 citations.
Papers
More filters
Journal ArticleDOI
FGF-21 as a novel metabolic regulator
Alexei Kharitonenkov,Tatiyana L. Shiyanova,Anja Koester,Amy M. Ford,Radmila Micanovic,Elizabeth Galbreath,George E. Sandusky,Lisa Janine Hammond,Julie S. Moyers,Owens Rebecca Anne,Jesper Gromada,Joseph T. Brozinick,Eric D. Hawkins,Victor J. Wroblewski,De Shan Li,Farrokh Mehrbod,S. Richard Jaskunas,Armen B. Shanafelt +17 more
TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Journal ArticleDOI
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun,Kyle W. Sloop,Corina Loghin,Jorge Alsina-Fernandez,Shweta Urva,Krister Bokvist,Xuewei Cui,Daniel A. Briere,Over Cabrera,William C. Roell,Uma Kuchibhotla,Julie S. Moyers,Charles Benson,Ruth E. Gimeno,David A. D'Alessio,Axel Haupt +15 more
TL;DR: LY3298176 showed glucose-dependent insulin secretion and improved glucose tolerance by acting on both GIP and GLP-1 receptors in mice and has the potential to deliver clinically meaningful improvement in glycaemic control and body weight.
Journal ArticleDOI
FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho.
Alexei Kharitonenkov,James D. Dunbar,Holly A. Bina,Stuart W. Bright,Julie S. Moyers,Chen Zhang,Liyun Ding,Radmila Micanovic,Sean F. Mehrbod,Michael D. Knierman,John E. Hale,Tamer Coskun,Armen B. Shanafelt +12 more
TL;DR: Results indicate that βKlotho and FGFRs form the cognate FGF‐21 receptor complex, mediating F GF‐21 cellular specificity and physiological effects.
Journal ArticleDOI
Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling
Julie S. Moyers,Tatiyana L. Shiyanova,Farrokh Mehrbod,James D. Dunbar,Timothy Wayne Noblitt,Keith A. Otto,Anne Reifel-Miller,Alexei Kharitonenkov +7 more
TL;DR: Treatment of cells with FGF‐21 and rosiglitazone in combination leads to a pronounced increase in expression of the GLUT1 glucose transporter and a marked synergy in stimulation of glucose transport, revealing a novel synergy between two regulators of glucose homeostasis, FGF-21 and PPARγ.
Journal ArticleDOI
Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
Kyle W. Sloop,Julia Xiao-Chun Cao,Angela M. Siesky,Hong Yan Zhang,Diane M. Bodenmiller,Amy L. Cox,Steven J. Jacobs,Julie S. Moyers,Owens Rebecca Anne,Aaron D. Showalter,Martin B. Brenner,Achim Raap,Jesper Gromada,Brian R. Berridge,David Monteith,Niels Pørksen,Robert Mckay,Brett P. Monia,Sanjay Bhanot,Lynnetta Watts,M. Dodson Michael +20 more
TL;DR: Together, these studies identify a novel mechanism whereby GCGR inhibitors reverse the diabetes phenotype by the dual action of decreasing hepatic glucose production and improving pancreatic beta cell function.